This investigational research study evaluated the dose response of once-weekly injections in patients with Type 2 Diabetes between 18 and 64 years of age.

The total study participation was approximately 1 year.

Qualified participants:

  • Generally adults; 18-64 years of age
  • BMI ≥0 kg/m2
  • Diagnosed with Type 2 Diabetes
  • Had an HbA1c between 7.0-10.5%

Stay on track with clinical trials you can trust.

Get in touch with us today and subscribe to our newsletter to see how we can provide the clinical trial and scientific consulting services you need.